Immunocore Holdings plc (IMCR)

↓ Download CSV

CIK 0001671927 · Nasdaq · Biological Products, (No Diagnostic Substances)

  • Sector Manufacturing
  • Incorporated X0
  • Fiscal year ends Dec 31

In fiscal 2025, Immunocore Holdings plc reported revenue of $400.02M, up 29.0% from the prior year. The company ran a net loss, with a net margin of -8.9%. It held $1.07B in total assets against $686.24M in total liabilities.

Key ratios (FY2025)

-11.3%
Operating margin
-8.9%
Net margin
-9.3%
Return on equity
+29.0%
Revenue growth (YoY)
Metric (FY)202520242023202220212020
Revenue$400.02M$310.20M$249.43M$174.36M$4.08M
Cost of Revenue$5.09M$2.73M$1.04M$1.09M$0
Operating Income-$45.35M-$70.46M-$59.65M-$51.71M-$174.59M
Net Income-$35.51M-$51.09M-$55.29M-$52.54M-$180.03M
EPS (Diluted)$-0.71$-1.02$-1.13$-1.15$-4.24
Total Assets$1.07B$1.01B$597.00M$526.76M
Total Liabilities$686.24M$648.79M$228.16M$187.86M
Shareholders' Equity$381.03M$360.72M$368.84M$338.90M$233.71M$76.91M
Cash & Equivalents$467.71M$455.73M$442.63M$402.47M
Operating Cash Flow-$10.71M$26.06M$2.94M-$49.21M-$143.11M
Capital Expenditures$4.34M$5.17M$5.42M$2.20M$1.39M
Shares Outstanding50.35M49.99M48.89M45.71M42.49M
Dividends Per Share$0.00$0.00$0.00$0.00